Synthesis and anticonvulsant properties of new n-mannich bases derived from 3,3-diphenyl- and 3-ethyl-3-methyl-pyrrolidine-2,5-diones. Part III

Archiv der Pharmazie

Volumn 346, Issue 1, 2013, Pages 71-82

  Obniska, Jolanta ^a   Chlebek, Iwona ^a   Kamiński, Krzysztof ^a   Karolak Wojciechowska, Janina ^b  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b LODZ UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

3,3 Disubstituted pyrrolidine 2,5 diones; Anticonvulsant activity; In vitro studies; In vivo studies; Mannich bases; Sodium channels

Indexed keywords

ANTICONVULSIVE AGENT; ETHOSUXIMIDE; N [(4 PHENYLPIPERAZIN 1 YL)METHYL] 3,3 DIPHENYLPYRROLIDINE 2,5 DIONE; N [[4 (2 CHLOROPHENYL)PIPERAZIN 1 YL]METHYL] 3 ETHYL 3 METHYLPYRROLIDINE 2,5 DIONE; N [[4 (2 CHLOROPHENYL)PIPERAZIN 1 YL]METHYL] 3,3 DIPHENYLPYRROLIDINE 2,5 DIONE; N [[4 (2 FLUOROPHENYL)PIPERAZIN 1 YL]METHYL] 3 ETHYL 3 METHYLPYRROLIDINE 2,5 DIONE; N [[4 (2 FLUOROPHENYL)PIPERAZIN 1 YL]METHYL] 3,3 DIPHENYLPYRROLIDINE 2,5 DIONE; N [[4 (2 METHOXYPHENYL)PIPERAZIN 1 YL]METHYL] 3 ETHYL 3 METHYLPYRROLIDINE 2,5 DIONE; N [[4 (2 METHOXYPHENYL)PIPERAZIN 1 YL]METHYL] 3,3 DIPHENYLPYRROLIDINE 2,5 DIONE; N [[4 (2 METHYLPHENYL)PIPERAZIN 1 YL]METHYL] 3 ETHYL 3 METHYLPYRROLIDINE 2,5 DIONE; N [[4 (2 METHYLPHENYL)PIPERAZIN 1 YL]METHYL] 3,3 DIPHENYLPYRROLIDINE 2,5 DIONE; N [[4 (3 CHLOROPHENYL)PIPERAZIN 1 YL]METHYL] 3 ETHYL 3 METHYLPYRROLIDINE 2,5 DIONE; N [[4 (3 CHLOROPHENYL)PIPERAZIN 1 YL]METHYL] 3,3 DIPHENYLPYRROLIDINE 2,5 DIONE; N [[4 (3 METHOXYPHENYL)PIPERAZIN 1 YL]METHYL] 3 ETHYL 3 METHYLPYRROLIDINE 2,5 DIONE; N [[4 (3 METHOXYPHENYL)PIPERAZIN 1 YL]METHYL] 3,3 DIPHENYLPYRROLIDINE 2,5 DIONE; N [[4 (3 METHYLPHENYL)PIPERAZIN 1 YL]METHYL] 3 ETHYL 3 METHYLPYRROLIDINE 2,5 DIONE; N [[4 (3 METHYLPHENYL)PIPERAZIN 1 YL]METHYL] 3,3 DIPHENYLPYRROLIDINE 2,5 DIONE; N [[4 (3 TRIFLUOROMETHYLPHENYL)PIPERAZIN 1 YL]METHYL] 3 ETHYL 3 METHYLPYRROLIDINE 2,5 DIONE; N [[4 (3 TRIFLUOROMETHYLPHENYL)PIPERAZIN 1 YL]METHYL] 3,3 DIPHENYLPYRROLIDINE 2,5 DIONE; N [[4 (3,4 DICHLOROPHENYL)PIPERAZIN 1 YL]METHYL] 3 ETHYL 3 METHYLPYRROLIDINE 2,5 DIONE; N [[4 (3,4 DICHLOROPHENYL)PIPERAZIN 1 YL]METHYL] 3,3 DIPHENYLPYRROLIDINE 2,5 DIONE; N [[4 (4 CHLOROPHENYL)PIPERAZIN 1 YL]METHYL] 3 ETHYL 3 METHYLPYRROLIDINE 2,5 DIONE; N [[4 (4 CHLOROPHENYL)PIPERAZIN 1 YL]METHYL] 3,3 DIPHENYLPYRROLIDINE 2,5 DIONE; N [[4 (4 FLUOROPHENYL)PIPERAZIN 1 YL]METHYL] 3 ETHYL 3 METHYLPYRROLIDINE 2,5 DIONE; N [[4 (4 FLUOROPHENYL)PIPERAZIN 1 YL]METHYL] 3,3 DIPHENYLPYRROLIDINE 2,5 DIONE; N [[4 PHENYLPIPERAZIN 1 YL]METHYL] 3,3 DIPHENYLPYRROLIDINE 2,5 DIONE; PHENYTOIN; PYRROLIDINE DERIVATIVE; SODIUM CHANNEL NAV1.2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CRYSTALLOGRAPHY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; IN VITRO STUDY; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SEIZURE; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTICONVULSANTS; CRYSTALLOGRAPHY, X-RAY; DISEASE MODELS, ANIMAL; MALE; MANNICH BASES; MICE; NAV1.2 VOLTAGE-GATED SODIUM CHANNEL; PENTYLENETETRAZOLE; RATS; RATS, SPRAGUE-DAWLEY; SEIZURES; STRUCTURE-ACTIVITY RELATIONSHIP; SUCCINIMIDES; TOXICITY TESTS, ACUTE;

EID: 84872271432     PISSN: 03656233     EISSN: 15214184     Source Type: Journal    
DOI: 10.1002/ardp.201200265     Document Type: Article

References (45)

1. B. S. Chang, D. H. Lowenstein, N. Eng. J. Med. 2003, 349, 1257-1266.
2. J. O. McNamara, Pharmacotherapy of the epilepsies, in Goodman & Gilman's The Phamacological Basis of Therapeutics, 12th ed. (Eds.:, L. L. Brunton, B. A. Chabner, B. C. Knollmann,), McGraw-Hill, New York 2011, pp. 583-608.
3. M. C. Picot, M. Baldy-Moulinier, J. P. Daurs, P. Dujols, A. Crespel, Epilepsia 2008, 49, 1230-1238.
4. J. A. Cramer, S. Mintzer, J. Wheless, R. H. Mattson, Expert Rev. Neurother. 2010, 10, 885-891.
5. H. N. Khan, S. Kulsoom, H. Rashid, Epilepsy Res. 2012, 98, 62-71.
6. M. G. Wong, J. A. Defina, P. R. Andrews, J. Med. Chem. 1986, 29, 562-572.
7. S. M. Tasso, L. E. Bruno-Blanch, S. C. Moon, G. L. Estiú, J. Mol. Struct. 2000, 504, 229-240.
8. M. A. Rogawski, Epilepsy Res. 2006, 69, 273-294.
9. M. A. Rogawski, W. Löscher, Nat. Rev. Neurosci. 2004, 5, 553-564.
10. R. K. Ellerkmann, S. Remy, J. Chen, D. Sochivko, C. E. Elger, B. W. Urban, A. Becker, H. Beck, Neuroscience 2003, 119, 323-333.
11. W. A. Catterall, Neuron 2000, 26, 13-25.
12. K. Kamiński, J. Obniska, B. Wiklik, D. Atamanyuk, Eur. J. Med. Chem. 2011, 46, 4634-4641.
13. K. Kamiński, S. Rzepka, J. Obniska, Bioorg. Med. Chem. Lett. 2011, 21, 5800-5803.
14. J. Obniska, M. Kopytko, A. Zagórska, I. Chlebek, K. Kamiński, Arch. Pharm. Chem. Life Sci. 2010, 343, 333-341.
15. K. Kamiński, J. Obniska, Bioorg. Med. Chem. 2008, 16, 4921-4931.
16. J. Obniska, K. Kamiński, A. Dzierzawska-Majewska, A. Zagórska, J. Karolak-Wojciechowska, J. Fluorine Chem. 2006, 127, 417-425.
17. J. Obniska, H. Byrtus, K. Kamiński, M. Pawłowski, M. Szczesio, J. Karolak-Wojciechowska, Bioorg. Med. Chem. 2010, 18, 6134-6142.
18. J. Obniska, K. Kamiński, D. Skrzyńska, J. Pichór, Eur. J. Med. Chem. 2009, 44, 2224-2233.
19. J. Obniska, A. Zagórska, Il Farmaco 2003, 58, 1227-1234.
20. A. Queen, Chem. L. Ind. 1958, 196.
21. A. Zejc, Dissertationes Pharm. Pharmacol. 1967, 19, 343-349.
22. J. P. Stables, H. J. Kupferberg, The NIH anticonvulsant drug development (ADD) program: preclinical anticonvulsant screening project, in Molecular and Cellular Targets for Antiepileptic Drugs (Eds.:, G. Avanzini, G. Regesta, O. Tanganelli, M. Avoli,), John Libby & Company Ltd, London 1997, pp. 191-198.
23. W. Löscher, Seizure 2011, 20, 359-368.
24. M. A. Rogawski, Epilepsy Res. 2006, 68, 22-28.
25. B. S. Meldrum, M. A. Rogawski, Neurotherapeutics 2007, 4, 18-61.
26. G. Liu, V. Yarov-Yarovoy, M. Nobbs, J. J. Clare, T. Scheuer, W. A. Catterall, Neuropharmacology 2003, 44, 413-422.
27. M. Bialer, S. I. Johannessen, R. H. Levy, E. Perucca, T. Tomson, S. White, Epilepsy Res. 2009, 83, 1-43.
28. C. R. Creveling, Mol. Pharmacol. 1983, 23, 350-358.
29. V. L. Trainer, D. Guedin, D. G. Baden, W. A. Catterall, J. Biol. Chem. 1993, 268, 17114-17119.
30. P. J. Jones, E. C. Merrick, T. W. Batts, N. J. Hargus, Y. Wang, J. P. Stables, E. H. Bertram, M. L. Brown, M. K. Patel, J. Pharmacol. Exp. Ther. 2009, 328, 201-212.
31. A. Dzierzawska-Majewska, L. Obniska, J. Karolak-Wojciechowska, J. Mol. Struct. 2006, 783, 66-72.
32. J. Karolak-Wojciechowska, A. Dzierzawska-Majewska, J. Obniska, J. Mol. Struct. 2008, 876, 294-300.
33. J. Karolak-Wojciechowska, A. Dzierzawska-Majewska, J. Obniska, Acta Cryst. E 2006, E62, 931.
34. J. Karolak-Wojciechowska, A. Dzierzawska-Majewska, J. Obniska, J. Mol. Struct. 2008, 888, 13-18.
35. R. L. Krall, J. K. Penry, B. G. White, H. J. Kupferberg, E. A. Swinyard, Epilepsia 1978, 19, 409-428.
36. H. J. Kupferberg, Epilepsia 1989, 30 (Suppl), 51-56.
37. E. A. Swinyard, J. H. Woodhead, H. S. White, M. R. Franklin, General principles: experimental selection, quantification, and evaluation of anticonvulsants, in Antiepileptic Drugs (Eds.:, R. H. Levy, R. H. M. Melrum, J. K. Penry, F. E. Dreifuss,), Raven Press, New York 1989, pp. 43-44.
38. H. S. White, M. Johnson, H. H. Wolf, H. J. Kupferberg, Ital. J. Neurol. Sci. 1995, 16, 73-77.
39. E. A. Swinyard, L. D. Clark, J. T. Miyahara, H. H. Wolf, J. Physiol. 1961, 132, 97-102.
40. N. W. Dunham, T. A. Miya, J. Am. Pharm. Assoc. Sci. 1957, 46, 208-209.
41. R. J. Racine, Electroencephalogr. Clin. Neurophysiol. 1972, 32, 281-294.
42. G. M. Sheldrick, Acta Crystallogr. Section A 2008, 64, 112-122.
43. R. Thirumurugan, D. Sriram, A. Saxena, J. Stables, P. Yogeeswari, Bioorg. Med. Chem. 2006, 14, 3106-3112.
44. P. Yogeeswari, D. Sriram, R. Thirumurugan, J. V. Raghavendran, K. Sudhan, P. K. Pavana, J. P. Stables, J. Med. Chem. 2005, 48, 6202-6211.
45. H. S. White, J. H. Woodhead, K. S. Wilcox, J. P. Stables, H. J. Kupferberg, H. H. Wolf, Discovery and preclinical development of antiepileptic drugs, in Antiepileptic Drugs (Eds.:, R. H. Levy, R. H. Mattson, B. S. Meldrum, E. Perucca,), Lippincott, Philadelphia, PA 2002, pp. 43-44.